New CRN VP
This article was originally published in The Tan Sheet
Executive Summary
The Council for Responsible Nutrition announces Dec. 11 Robert Borris, PhD, will become the association's vice president-botanical science and regulatory affairs, effective Jan. 2, 2007. CRN says Borris will be responsible for "increasing the awareness of the evolving body of botanical research that supports an appropriate role for plant-based dietary supplements." Borris previously worked for Merck Research Laboratories for more than two decades, according to the release. He headed the phytochemistry program and its two major biodiversity collaborations with INBio and the New York Botanical Garden, according to CRN. The trade group's President & CEO Steve Mister says: "We are excited to welcome Dr. Borris to CRN's team. His specific expertise makes our well-respected scientific team even stronger and rounds out our coverage of all supplement categories." CRN most recently appointed Andrew Shao, PhD, VP-scientific and regulatory affairs in April 2005 (1"The Tan Sheet" April 4, 2005, In Brief)...
You may also be interested in...
CRN appointment
Andrew Shao, PhD, has been appointed VP-scientific & regulatory affairs for the Council for Responsible Nutrition, the association announces April 1. Shao previously served as a senior scientist for GNC, where he reviewed new products and ingredients to determine their scientific viability and applications. John Hathcock, PhD, will continue to serve as VP-scientific & international affairs. The appointment closely follows that of incoming CRN President Steve Mister, who will assume his role later this month (1"The Tan Sheet" March 14, 2005, p. 8)...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.